The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
ANTERIOR CHAMBER ASSOCIATED IMMUNE DEVIATION (ACAID): REGULATION, BIOLOGICAL RELEVANCE, AND IMPLICATIONS FOR THERAPY
Abstract
Immune privilege was first explored in the late 1800s by van Dooremaal, and was then extended by Medawar in the mid 1900s to fit in with emerging concepts of transplantation immunology. Modern concepts and understanding of immune privilege come from subsequent studies produced by Medawar, Billingham, and Streilein. The exploitation of the model of anterior chamber immune deviation (ACAID) in mice has allowed us to look at both cellular and molecular mechanisms involved in the prevention of potentially damaging immune responses in such privileged sites. This review gives a historical perspective of the immune privilege research and provides up-to-date information of molecules, cells, and concepts newly recognized as contributing to tolerance induction induced in such specialized areas of the body. Evidence is given to support the idea that application of such information may lead to potential for therapeutic applications of ACAID mechanisms in prevention of progression of immune-inflammatory diseases in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“subretinally delivered vectors elicit a relatively reduced immune response akin to anterior chamber-associated immune deviation (ACAID).93,94”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [94]
Citations
Cites
Mosmann, T. R., & Coffman, R. L. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.001045 · Cited by 7,692
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Requirement for V α 14 NKT Cells in IL-12-Mediated Rejection of Tumors
Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., & Taniguchi, M. (1997) · Science · doi:10.1126/science.278.5343.1623 · Cited by 1,237
CD1 Recognition by Mouse NK1 + T Lymphocytes
Bendelac, A., Lantz, O., Quimby, M. E., Yewdell, J. W., Bennink, J. R., & Brutkiewicz, R. R. (1995) · Science · doi:10.1126/science.7538697 · Cited by 914
Weiner, H. L. (1994) · Annual Review of Immunology · doi:10.1146/annurev.immunol.12.1.809 · Cited by 906
Immunologically Privileged Sites
Barker, C. F., & Billingham, R. E. (1978) · Advances in Immunology · doi:10.1016/s0065-2776(08)60930-x · Cited by 815
Porcelli, S., Yockey, C. E., Brenner, M. B., & Balk, S. P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.1.1 · Cited by 756
Oral tolerance: immune mechanisms and treatment of autoimmune diseases
Weiner, H. L. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01053-0 · Cited by 731
Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view
Cserr, H. F., & Knopf, P. M. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90027-5 · Cited by 653
Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes
Wilson, S. B., Kent, S. C., Patton, K. T., Orban, T., Jackson, R. A., Exley, M., Porcelli, S., Schatz, D. A., Atkinson, M. A., Balk, S. P., et al. (1998) · Nature · doi:10.1038/34419 · Cited by 646
Research works printed but not linked: 44
- van Dooremaal J.C., 1873, Akbrecg. Vab. Graefes Arch. Opthalomol., 19, 358
- P.B., 1945, London, 79, 157
- P.B., 1948, Pathol., 29, 58
- Streilein J.W., 1979, Masson et Cie, 174
- Asherson G.L., 1965, Immunology, 9, 205
- Niederkorn J., 1980, Invest. Opthalmol. Vis. Sci., 20, 355
- Whittum J.A., 1984, Invest. Opthalmol. Vis. Sci., 25, 1065
- McLeish W., 1989, Regional Immunol., 2, 236
- Niederkorn J.Y., 1990, Adv. Immunol., 48, 1999
- Mizuno K., 1989, Invest. Ophthalmol. Vis. Sci., 30, 1112
- Streilein J.W., 2001, Invest. Ophthalmol. Vis. Sci., 42, S523
- Jiang L.Q., 1991, Invest. Ophthalmol. Vis. Sci., 32, 224
- Jiang L.Q., 1993, Invest. Opthahalmol. Vis. Sci., 34, 3347
- Eichorn M., 1993, Invest. Ophthalmol. Vis. Sci., 34, 2926
- Kaiser C.J., 1985, Regional Immunol., 2, 42
- Taylor A.W., 1998, Invest. Opthahalmol. Vis. Sci., 39, 1372
- Miyamoto K.I., 1999, Invest. Ophthalmol. Vis. Sci., 40, S986
- Takeuchi M., 1999, Immunol., 98576
- Goslings R.O., 1998, Invest. Ophthalmol. Vis. Sci., 39, 989
- Cousins S.W., 1991, Invest. Ophthalmol. Vis. Sci., 32, 2201
- Biros D.J., 2001, Invest. Ophthalmol. Vis. Sci., 42, S929
- Knisely T.L., 1994, Invest. Opthalmol. Vis. Sci., 35, 3711
- Williamson S.P., 1989, Immunology, 67, 96
- H., 1989, The Journal of Immunology, 153, 1982
- Kezuka T., 2000, Immunology, 41, 1410
- Yao Y.F., 1997, Invest. Ophthalmol. Vis. Sci., 38, 534
- Kezuka T., 2000, Invest. Ophthalmol. Vis. Sci., 41, 1803
- Kezuka T., 2000, Invest. Ophthalmol. Vis. Sci., 41, 1410
- Waldrep J.C., 1984, Invest. Opthalmol. Vis. Sci., 25, 447
- Wilbanks G., 1990, Immunology, 71, 383
- Martin F., 2000, Immunol. Rev., 175, 70, 10.1111/j.1600-065X.2000.imr017515.x · doi:10.1111/j.1600-065x.2000.imr017515.x · Paper page
- Sonoda K.-H., 2001, Invest. Opthalmol. Vis. Sci., 42, S930
- Sonoda K.-H., 2001, Stein-Streilein. J. Immunol., 166, 42
- Faunce D.E., 2001, Invest. Opthalmol. Vis. Sci., 42, S930
- T., 1999, Cancer Res., 59, 5102
- Parker D.C., 1992, FASEB J., 131, 2777
- Wilbanks G.A., 1989, Regional Immunol., 2, 390
- Wilbanks G.A., 1990, Immunology, 71, 383
- 10.1146/annurev.iy.12.040194.004113 · doi:10.1146/annurev.iy.12.040194.004113 · Paper page
- Mosmann T.R., 1992, Sci., 664, 89
- Wilbanks G.A., 1990, Immunology, 71, 566
- Atherton S.S., 1987, Invest. Opthamol. Vis. Sci., 28, 859
- Rouse M.G., 1992, J. Immunol., 142, 3035
- Niederkorn J.Y., 1996, Invest. Ophthalmol. Vis. Sci., 37, 2700
Cited by
TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells
Marie, J. C., Letterio, J. J., Gavin, M., & Rudensky, A. Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042276 · Cited by 985
“Nevertheless, it will be of interest to experimentally test whether substantial amounts of TGF- 1 displayed by some immunoprivileged tissues and organs, like the ocular chamber of the eye, can facilitate maintenance, expansion, or de novo generation of antigen-specific T reg cells (27).”
BackgroundOcular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807
Self-citationCNS immune privilege: hiding in plain sight
Carson, M. J., Doose, J. M., Melchior, B., Schmid, C. D., & Ploix, C. C. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00441.x · Cited by 795
“Within the CNS, Streilein and colleagues (112) were among the first to provide evidence that CNS antigens were not hidden from the immune system.”
BackgroundCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Unlike systemically delivered AAV, subretinally delivered vectors elicit a relatively reduced immune response akin to anterior chamber-associated immune deviation (ACAID).(93,94) However, SRI is a challenging technique, described as “almost a subspecialty unto itself.”
BackgroundA look at autoimmunity and inflammation in the eye
Caspi, R. R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42440 · Cited by 482
“There, it induces the generation of antigen-specific CD4+ and CD8+ regulatory T cells through a complex mechanism involving B cells and NKT cells (64).”
Background
Metadata
- Authors
- STEIN-STREILEIN, J., & STREILEIN, J. W.
- Affiliations
- Harvard University (US)
- Venue
- International Reviews of Immunology
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 21
- Issue
- 2-3
- Pages
- 123-152
- ISSN
- 0883-0185 (ISSN-L)
- 1563-5244
- OpenAlex
- W1966161103
- Cited by
- 218
- References
- 132
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 11 · 2017: 5 · 2016: 7 · 2015: 9 · 2014: 5 · 2013: 7 · 2012: 11
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Reviews of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- anterior chamber-associated immune deviation, immune privilege, tolerance induction, ocular immunology, transplantation immunology
- MeSH terms
- Animals, Anterior Chamber, Antigen-Presenting Cells, Eye Diseases, Graft vs Host Disease, Humans, Immune Tolerance, Killer Cells, Natural, Ovalbumin, T-Lymphocytes, Transplantation Immunology, Th1 Cells, Th2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ANTERIOR CHAMBER ASSOCIATED IMMUNE DEVIATION (ACAID): REGULATION, BIOLOGICAL RELEVANCE, AND IMPLICATIONS FOR THERAPY. https://app.cochat.ai/papers/10.1080/08830180212066
- The paper
- STEIN-STREILEIN, J., & STREILEIN, J. W. (2002). ANTERIOR CHAMBER ASSOCIATED IMMUNE DEVIATION (ACAID): REGULATION, BIOLOGICAL RELEVANCE, AND IMPLICATIONS FOR THERAPY. International Reviews of Immunology. https://doi.org/10.1080/08830180212066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.